One unidentified substance is likely the parent compound and the other is likely a GC/MS analytical artifact / breakdown product of the primary substance.
Unidentified Substance #1: 1 part
Unidentified Substance #2: 2 parts
Sep 20 2023: The previously unidentified substances in this sample have been tentatively identified as Rilmazafone and a GC/MS analytical artifact / breakdown product of Rilmazafone.
This substance was identified through the Erowid Expert Network.
Aug 31 2023: A certified reference standard for Rilmazafone (CAS # 99593-25-6) does not seem to be available.
Send in a sample for testing
DrugsData tests all psychoactive drugs including ecstasy tablets, powders, research chemicals, novel pschoactive substances, and other drugs through our DEA-licensed laboratory. Ecstasy/Molly tablets cost $100. Recreational drug powder/crystal/blotter costs $100. Pharmaceuticals, supplements and all others cost $150 per analysis.
Should the public have access to independent analysis of the products they consume?
The vast majority of analyses of over-the-counter, prescription, and recreational drugs are performed in secret with no independent oversite or review. No other historical record, free from politically-controlled agencies, is currently available in North America nor most other parts of the world.
DrugsData, a project of Erowid Center, needs the support of professionals, students, parents, individuals with means, and small foundations for a total yearly budget of around $120,000 USD. Erowid Center's general budget and the co-pays we require fund most of this cost.
Unidentified Substance #1: 1 part
Unidentified Substance #2: 2 parts
This substance was identified through the Erowid Expert Network.
Aug 31 2023: A certified reference standard for Rilmazafone (CAS # 99593-25-6) does not seem to be available.